Neanderthal and Denisovan Glutamate Dehydrogenase 2 Evolution and Clinical Significance.

Yulia A Aleshina, Lev G Zavileyskiy, Vasily A Aleshin

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yulia A AleshinaMartsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia.ORCID 0000-0003-2791-1835

Lev G ZavileyskiyFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119234 Moscow, Russia.

Vasily A AleshinBelozersky Institute of Physicochemical Biology, Lomonosov Moscow State University, 119234 Moscow, Russia.ORCID 0000-0001-8984-4821

Funding

Russian Science Foundation 23-74-10036

6 · The paper itself

Abstract

Mammalian glutamate dehydrogenase (GDH) is an indispensable metabolic enzyme. GDH duplication has led to the presence of two paralogs, GDH1 and GDH2, in apes. Multiple GDH pseudogenes are also present in the human genome. The novel GDH2, supposed to be a target of positive selection, differs from GDH1 in regulation and is believed to be tightly linked to brain development. Although the differences of modern human GDH2 from GDH2 of other apes have been studied, the evolution of ancient human GDH2 remains a blank space. The goal of this work was to elucidate GDH2 evolution in the genus

Indexed as

Evolution, MolecularGlutamate DehydrogenaseHominidaeNeanderthalsAnimalsClinical RelevanceHumansMutation, MissensePhylogenyGlutamate DehydrogenaseDenisovanGLUD1P3GLUD2glutamate dehydrogenasehuman evolutionmiR-27NeanderthalParkinson’s disease

Identifiers

PMID40362558

DOI10.3390/ijms26094322

PMCPMC12072557

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.